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Objectives This study sought to identify incidence, predictors, and impact of vascular complications (VC) after transfemoral
(TF) transcatheter aortic valve replacement (TAVR).
Background VC after TF-TAVR are frequent and may be associated with unfavorable prognosis.
Methods From the randomized controlled PARTNER (Placement of AoRTic TraNscathetER Valve) trial, a total of 419 pa-
tients (177 from cohort B [inoperable] and 242 from cohort A [operable high-risk]) were randomly assigned to
TF-TAVR and actually received the designated treatment. First-generation Edwards-Sapien valves and delivery
systems were used, via a 22- or 24-F sheath. The 30-day rates of major and minor VC (modified Valve Academic
Research Consortium definitions), predictors, and effect on 1-year mortality were assessed.
Results Sixty-four patients (15.3%) had major VC and 50 patients (11.9%) had minor VC within 30 days of the proce-
dure. Among patients with major VC, vascular dissection (62.8%), perforation (31.3%), and access-site hema-
toma (22.9%) were the most frequent modes of presentation. Major VC, but not minor VC, were associated with
significantly higher 30-day rates of major bleeding, transfusions, and renal failure requiring dialysis, and with a
significantly higher rate of 30-day and 1-year mortality. The only identifiable independent predictor of major VC
was female gender (hazard ratio [HR]: 2.31 [95% confidence interval (CI): 1.08 to 4.98], p  0.03). Major VC
(HR: 2.31 [95% CI: 1.20 to 4.43], p  0.012), and renal disease at baseline (HR: 2.26 [95% CI: 1.34 to 3.81],
p  0.002) were identified as independent predictors of 1-year mortality.
Conclusions Major VC were frequent after TF-TAVR in the PARTNER trial using first-generation devices and were associated with
high mortality. However, the incidence and impact of major VC on 1-year mortality decreased with lower-risk
populations. (J Am Coll Cardiol 2012;60:1043–52) © 2012 by the American College of Cardiology Foundation
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Vascular Complications After TAVR September 18, 2012:1043–52Vascular complications (VC) after
transfemoral (TF) transcatheter
aortic valve replacement (TAVR)
are frequent and may be associated
with unfavorable clinical outcomes
(1–8). The use of large-diameter
catheters (18-F to 24-F) and the
high-risk characteristics of the
population treated in the early
days of TAVR may explain the
high incidence. Although the
PARTNER (Placement of AoRTic TraNscathetER Valve)
trial recently demonstrated that TAVR is associated with
similar mortality at 30 days and up to 2 years in surgical
high-risk patients compared with surgical aortic valve re-
placement (9,10), and that TAVR is superior to medical
treatment in patients not suitable for conventional surgery
(11,12), a number of TAVR-associated complications have
been identified, including a high incidence of VC. Pub-
lished studies using the first-generation devices showed an
incidence of major VC varying from 5% to 23% using
uniform definitions (13,14). Recently published data (7)
have suggested improvement in VC, due to the combination
of newer device generations, smaller delivery systems, and
the use of adjunctive techniques, combined with better
screening and increased operator experience (7). The aim of
this report is to better characterize the incidence, nature,
predictors, and impact of VC on long-term prognosis after
TF-TAVR from the multicenter, prospective randomized
PARTNER trial.
Methods
Study population. The design and initial results of the
ARTNER trial (cohort B and cohort A) have been
ublished previously (9,11). Briefly, the PARTNER trial
nrolled patients with severe symptomatic aortic stenosis.
atients were divided into 2 cohorts: those who were
onsidered to be candidates for surgery despite the fact that
participation on the Executive Committee of the PARTNER trial. Dr. Svensson has
received travel reimbursement from Edwards Lifesciences for activities related to his
participation on the Executive Committee of the PARTNER trial. Dr. Kodali has
received consulting fees from Edwards Lifesciences and Medtronic; and is a member
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Medical. Dr. Davidson received grant support and consulting fees from Edwards
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PARTNER 2 trial. Dr. Makkar has received grant support and travel reimbursements
from Edwards Lifesciences; consulting fees from Cordis, Medtronic, Abbott Vascu-
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and St. Jude Medical. Dr. Williams has received consulting fees from Edwards
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Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
TAVR  transcatheter
aortic valve replacement
TF  transfemoral
VC  vascular
complication(s)a
Manuscript received May 14, 2012; revised manuscript received June 29, 2012,
accepted July 2, 2012.they were at high surgical risk, as defined by a Society of
Thoracic Surgeons risk score of 10% or higher or by the
presence of coexisting conditions that would be associated
with a predicted risk of death by 30 days after surgery of
15% or higher (cohort A), and those who were not
considered to be suitable candidates for surgery because
they had coexisting conditions that would be associated
with a predicted probability of 50% or more of either
death by 30 days after surgery or a serious irreversible
condition (cohort B).
Patients from cohort B with a suitable iliofemoral vessel
were then randomized to TF-TAVR with the Edwards-
Sapien heart valve system (Edwards Lifesciences, Irvine,
California) or to standard medical care. Patients enrolled in
cohort A were then randomized to TAVR (TF if iliac and
femoral vessels were suitable or transapical if not) or to
conventional surgical aortic valve replacement. The current
analysis pooled patients from cohorts A and B who under-
went TAVR via TF approach only. The study was approved
by the institutional review board at each participating site,
and all patients provided written informed consent.
Study endpoint. VC were defined according to a modified
version of the Valve Academic Research Consortium crite-
ria as described in the PARTNER trial protocol (11,14).
Major VC were defined by the presence of any of the
following: 1) any thoracic aortic dissection; 2) access site or
access-related vascular injury (dissection, stenosis, perfora-
tion, rupture, arteriovenous fistula, pseudoaneurysm, hema-
toma, irreversible nerve injury, or compartment syndrome)
leading to either death, need for significant blood transfu-
sions (4 U), unplanned percutaneous (endovascular stent)
or surgical intervention, or irreversible end-organ damage;
3) distal embolization (noncerebral) from a vascular source
requiring surgery or resulting in amputation or irreversible
end-organ damage; or 4) left ventricular perforation. Minor
VC were defined by the presence of any of the following:
1) access site or access-related vascular injury (dissection,
stenosis, perforation, rupture, arteriovenous fistula or pseu-
doaneurysm requiring compression or thrombin injection
therapy, or hematomas requiring transfusion (2 but4 U)
ut not requiring unplanned percutaneous or surgical inter-
ention and not resulting in irreversible end-organ damage;
) distal embolization treated with embolectomy and/or
hrombectomy and not resulting in amputation or irrevers-
ble end-organ damage; and 3) failure of percutaneous
ccess site closure resulting in interventional (endovascular
tent) or surgical correction and not associated with death,
eed for significant blood transfusions (4 U), or irrevers-
ble end-organ damage.
The 30-day and 1-year frequency of all-cause mortality,
ardiovascular mortality, stroke, major bleeding, myocardial
nfarction, and acute kidney injury were reported according
o Valve Academic Research Consortium definitions (14).
ll adverse events were adjudicated by an independent
linical events committee. Independent core laboratories
nalyzed all echocardiograms and electrocardiograms. All
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September 18, 2012:1043–52 Vascular Complications After TAVRdata were sent for analysis to an independent academic
biostatistics group.
Statistical analysis. All the analyses were performed with
ata from the as-treated population, which included all
atients who underwent TF-TAVR as the final treatment
f the index procedure. Continuous variables are summa-
ized as mean  SD or medians and quartiles, as appropri-
te, and were compared using the Student t test or Mann-
hitney rank sum test accordingly. Categorical variables
ere compared by the chi-square or the Fisher exact test.
Baseline Clinical Characteristics of Patients According to the OccuTable 1 Baseline Clinical Characteristics of Patients According
Major Vascular
Complications (n  6
Age, yrs 83.61 [77.47–87.32]
Male 32.8% (21/64)
Female 67.2% (43/64)
BMI, kg/m2 25.34 [20.63–29.36]
BSA, m2 1.73 [1.57–1.89]
STS score 11.20 [8.80–14.00]
Logistic EuroSCORE 18.45 [13.60–35.84]
Any diabetes 39.1% (25/64)
Insulin 24.0% (6/25)
Hyperlipidemia 75.0% (48/64)
Smoking 39.1% (25/64)
Hypertension 85.7% (54/63)
CHF at baseline 95.3% (61/64)
NYHA functional class 2 9.4% (6/64)
NYHA functional class 3 35.9% (23/64)
NYHA functional class 4 54.7% (35/64)
CAD 65.6% (42/64)
Prior MI 15.6% (10/64)
Prior PCI 26.6% (17/64)
Prior CABG 32.8% (21/64)
Angina 31.3% (20/64)
Stable 90.0% (18/20)
Unstable 10.0% (2/20)
Cerebrovascular disease 19.4% (12/62)
Stroke or TIA (last 6–12 months) 19.4% (12/62)
Carotid disease 15.0% (9/60)
Peripheral vascular disease 37.5% (24/64)
Porcelain aorta 3.1% (2/64)
Prior BAV 15.6% (10/64)
Permanent pacemaker 23.4% (15/64)
Renal disease (creatinine 2 mg/dl [177 mol/l]) 20.3% (13/64)
Liver disease 1.6%(1/64)
Severe COPD 18.2% (8/44)
Oxygen dependent 10.9% (7/64)
Baseline laboratory values
WBC count, 103/l 7.34 [5.65–9.20]
HGB, g/dl 11.15 [10.50–12.60]
Platelets count, cells/mm3 212.50 [149.00–263.5
Creatinine, mg/dl 1.10 [0.91–1.50]
Albumin, g/dl 3.60 [3.10–4.10]
Values are median [interquartile range] or % (n/total N).
BAV balloon aortic valvuloplasty; BMI body mass index; BSA body surface area; CABG cobstructive pulmonary disease; HGB  hemoglobin; MI  myocardial infarction; NYHA  New York Hea
TIA  transient ischemic attack; VC  vascular complications; WBC  white blood cell.urvival curves for time-to-event variables were constructed
n the basis of all available follow-up data with the use of
aplan-Meier estimates and comparisons relied on the
og-rank test. Multivariate logistic regression was performed
o identify independent predictors of 30-day major VC
  0.05). The multivariable model was built by selecting
ariables of clinical interest and/or satisfying the entry
riterion of p  0.05 in the univariate analysis. Variables
included in the model were carefully selected to avoid
overfitting. All selected variables were entered at the
e of Major VC Up to 30 Dayshe Occurrence of Major VC Up to 30 Days
No Major Vascular
Complications (n  355)
Combined
(n  419) p Value
84.98 [79.95–88.58] 84.67 [79.70–88.48] 0.13
58.0% (206/355) 54.2% (227/419) 0.0002
42.0% (149/355) 45.8% (192/419) 0.0002
26.15 [22.80–30.18] 25.94 [22.38–30.04] 0.15
1.84 [1.64–2.01] 1.81 [1.63–2.00] 0.01
11.00 [9.30–13.40] 11.00 [9.30–13.90] 0.79
26.00 [14.56–39.00] 24.80 [14.20–38.09] 0.07
38.0% (135/355) 38.2% (160/419) 0.88
8.1% (11/135) 10.6% (17/160) 0.03
77.5% (275/355) 77.1% (323/419) 0.67
46.2% (164/355) 45.1% (189/419) 0.29
87.3% (310/355) 87.1% (364/418) 0.73
98.3% (349/355) 97.9% (410/419) 0.14
5.9% (21/355) 6.4% (27/419) 0.28
46.5% (165/355) 44.9% (188/419) 0.12
47.6% (169/355) 48.7% (204/419) 0.30
73.5% (261/355) 72.3% (303/419) 0.19
25.0% (88/352) 23.6% (98/416) 0.10
31.7% (112/353) 30.9% (129/417) 0.41
37.2% (132/355) 36.5% (153/419) 0.50
27.0% (96/355) 27.7% (116/419) 0.49
88.5% (85/96) 88.8% (103/116) 1.00
7.3% (7/96) 7.8% (9/116) 0.65
27.6% (94/340) 26.4% (106/402) 0.17
27.6% (94/340) 26.4% (106/402) 0.17
28.1% (94/335) 26.1% (103/395) 0.03
32.7% (115/352) 33.4% (139/416) 0.45
5.4% (19/355) 5.0% (21/419) 0.75
13.5% (48/355) 13.8% (58/419) 0.65
19.2% (68/355) 19.8% (83/419) 0.43
20.6% (73/354) 20.6% (86/418) 0.96
3.1% (11/354) 2.9% (12/418) 0.70
26.9% (64/238) 25.5% (72/282) 0.22
14.6% (52/355) 14.1% (59/419) 0.43
6.80 [5.70–8.60] 6.90 [5.70–8.65] 0.52
11.55 [10.60–12.80] 11.50 [10.60–12.80] 0.28
208.00 [165.00–266.00] 208.50 [163.00–264.00] 0.53
1.20 [0.96–1.60] 1.20 [0.94–1.60] 0.33
3.70 [3.30–4.10] 3.70 [3.30–4.10] 0.36
y artery bypass graft; CAD coronary artery disease; CHF cardiac heart failure; COPD chronicrrencto t
4)
0]
oronar
rt Association; PCI  percutaneous coronary intervention; STS  Society of Thoracic Surgeons;
m
SFAR 
c
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Vascular Complications After TAVR September 18, 2012:1043–52same time. To assess the association between major VC
and 1-year rate of all-cause mortality, Cox multivariable
regression analyses were performed, with variable selec-
tion performed as described in the preceding text. A
Figure 1 Distribution of Type of Major Vascular Complications
Vascular dissection, vessel perforation, and access site hematoma were the mos
Procedural Characteristics According to the Occurrence of VCs UpTable 2 Procedural Characteristics According to the Occurrenc
Major Vascular
Complications (n  64)
Valve size
23 mm (22-F sheath introducer) 60.3% (38/63)
26 mm (24-F sheath introducer) 39.7% (25/63)
Femoral vessel diameter,* mm 7.94 1.07 (49)
External Iliac vessel diameter,* mm 8.29 1.46 (49)
Iliac vessel diameter,* mm 9.07 1.94 (49)
SEIAR 1.08 0.16 (49)
SFAR 1.11 0.13 (49)
Severe tortuosity† 0.0% (0/53)
Severe calcification‡ 5.7% (3/53)
Access site
Right 51.6% (33/64)
Left 48.4% (31/64)
Artery closure
Surgical cutdown 85.7% (54/63)
Closure device 15.9% (10/63)
Study valve successfully implanted 95.2% (60/63)
Migration or embolization 5.8% (3/52)
Hemodynamic support (CPB or IABP) 11.1% (7/63)
Conversion to open heart surgery 7.9% (5/63)
Volume of contrast, ml 150.0 [100.0–250.0]
Heparin amount administrated, IU 8,000.0 [5,500.0–11,000.0]
Total procedure time, min 175.0 [145.0–297.0]
Fluoroscopy time, min 36.5 [26.0–47.0]
Day in hospital post-procedure 6.9 2.5
Values are % (n/total N), mean SD (n), or median [interquartile range]. *Data from computed tom
†Tortuosity was classified as follows: none; mild (30° to 60° bend); moderate (60° to 90° bend); a
ild, moderate, and severe as described by Hayashida et al. (8).
CPB  cardiopulmonary bypass, IABP  intra-aortic balloon pump, OR  operating room;
omplications.2-sided alpha level of 0.05 was used for all superiority
testing. All statistical analyses were performed with the
use of SAS software, version 9.2 (SAS Institute, Cary,
North Carolina).
Transcatheter Aortic Valve Replacement
ent causes of major vascular complications.
0 DaysVCs Up to 30 Days
No Major Vascular
mplications (n  355)
Combined
(n  419) p Value
49.3% (169/343) 51.0% (207/406) 0.11
50.7% (174/343) 49.0% (199/406) 0.11
8.39 1.28 (297) 8.32 1.26 (346) 0.007
8.71 1.38 (298) 8.65 1.40 (347) 0.02
9.70 1.71 (298) 9.61 1.75 (347) 0.009
0.99 0.23 (298) 1.00 0.22 (347) 0.02
1.03 0.24 (297) 1.04 0.23 (346) 0.01
3.2% (10/315) 2.7% (10/368) 0.37
5.7% (18/315) 5.7% (21/368) 1.00
50.4% (174/345) 50.6% (207/409) 0.87
49.6% (171/345) 49.4% (202/409) 0.87
75.2% (261/347) 76.8% (315/410) 0.07
26.5% (92/347) 24.9% (102/410) 0.10
97.1% (336/346) 96.8% (396/409) 0.43
1.0% (3/299) 1.7% (6/351) 0.04
1.4% (5/347) 2.9% (12/410) 0.0006
0.9% (3/347) 2.0% (8/410) 0.003
0.00 [80.00–170.00] 125.0 [80.0–180.0] 0.0008
0.0 [5,000.0–10,000.0] 7,000.0 [5,000.0–10,000.0] 0.05
15.0 [92.0–154.0] 122.0 [94.0–169.0] 0.0001
26.0 [21.0–32.0] 27.0 [21.0–35.0] 0.0001
5.8 2.3 5.9 2.3 0.006
y or peripheral intravascular ultrasound assessment of the access site used for the index procedure.
re (90° bend) as described by Hayashida et al. (8). ‡Calcification was classified as follow: none,
sheath- to-femoral-artery ratio; SEIAR  sheath-to-external-iliac-artery ratio; VC  vascularAfter
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September 18, 2012:1043–52 Vascular Complications After TAVRResults
Patients and baseline characteristics. Among the 699
patients enrolled in the PARTNER trial cohort A and the
358 patients enrolled in the PARTNER trial cohort B, 244
and 179, respectively, were randomized to TF-TAVR from
these patients, 242 from cohort A and 177 from cohort B
(n  419) were actually treated via TF access and were
ncluded in this analysis. Among them, 64 (15.3%) had a
ajor VC and 50 (11.9%) had a minor VC within 30 days
f the index procedure. Baseline and procedural character-
stics of patients stratified by occurrence of major VC within
0 days are shown in Tables 1 and 2. Compared with
patients with no major VC, patients with major VC were
more frequently female, had a lower body surface area, more
frequently had insulin-treated diabetes at baseline, had
smaller vessel diameter, and had higher sheath-to-femoral-
artery ratio and sheath-to-external-iliac-artery ratio. During
the procedure, major VC were associated with higher rates
Management StrategiesAmon 64 Patients With Major VCTable 3 Man gement StrategiesAmong 64 Patients With Major VC
Surgical (open) 54.9% (35)
Endovascular 45.5% (29)
Balloon only 6.5% (4)
Open cell stent 22.1% (14)
Stent graft 23.4% (15)
Values are % (n). A combination or sequence involving more than 1 strategies is possible.
VC  vascular complications.
Figure 2 Difference in Rates of VC From Cohort 1B to Cohort 1
The rates of all vascular complications (VC), vascular dissection, and access site
suggesting improved outcomes in a lower-risk population and with more experiencof embolization or migration of the prosthesis, use of
hemodynamic support devices, and conversion to open heart
surgery. The index procedure was longer in the major VC
group, with more contrast used, and longer fluoroscopy
time. Access and closure of the access site was performed in
76.8% of patients by surgical cutdown, whereas suture-based
closure device systems were used in 24.9% of the complete
cohort. Surgical cutdown was used more frequently in the
major VC group (85.7% vs. 75.2%, p  0.07), whereas a
complete percutaneous approach using closure devices was
used more often in the non-major VC group (15.9% vs.
26.5%, p  0.1). The duration of hospitalization after the
rocedure was longer in the major VC group (6.9  2.5
ays vs. 5.8  2.3 days, p  0.006).
linical outcomes. Types of major VC and their 30-day
ates of occurrence are shown in Figure 1. Vascular dissec-
ion, vascular perforation, and access site hematoma were
ost frequently reported. Three cases (0.7%) of aortic
issection and 2 cases (0.5%) of left ventricle perforation
ere reported. Table 3 shows strategies used to manage
ajor VC. Thirty-day rates for major, minor, and the
ifferent types of VC stratified by PARTNER cohort
cohort B vs. A) are shown in Figure 2.
Clinical outcomes of patients stratified by major VC
ersus no major VC are shown in Table 4 and in Figure 3.
he occurrence of major VC after TAVR was associated
ith significantly higher 30-day rates of major bleeding and
ransfusions, and with significantly higher rates of 30-day
oma decreased from cohort 1B to cohort 1A,
rators. TF  transfemoral.A
hemat
ed ope
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Vascular Complications After TAVR September 18, 2012:1043–52and 1-year all-cause and cardiac mortality. Major VC were
also associated with a significantly higher rate of renal
failure requiring dialysis at 30 days. Clinical outcomes of
patients stratified by minor VC versus no vascular compli-
cation are shown in Table 5 and Figure 4. At 30 days and
1 year, the occurrence of minor VC was not associated with
higher mortality, major bleeding, transfusions, or acute kidney
injury requiring dialysis compared with patients with no VC
at all.
Multivariate analysis. Variables associated with major VC
are shown in Table 6. After multivariable analysis, female
sex was identified as the strongest independent predictor of
major VC (hazard ratio [HR]: 2.31 [95% confidence inter-
val (CI): 1.08 to 4.98], p  0.03). A multivariate Cox
proportional hazard analysis including patients from both
cohorts identified major VC (HR: 2.31 [95% CI: 1.20 to
4.43], p  0.012) and renal disease at baseline (HR: 2.26
95% CI: 1.34 to 3.81], p  0.002) as independent
30-Day and 1-Year Event Rates According to the Occurrence of MaTable 4 30-Day and 1-Year Event Rates According to the Occu
Major Vascular
Complications (n  64)
30-day events
Death
From any cause 14.1% (9)
From cardiovascular cause 12.6% (8)
Stroke or TIA 6.4% (4)
TIA 1.6% (1)
Stroke 4.8% (3)
Minor 3.3% (2)
Major 1.6% (1)
Death from any cause or major stroke 14.1% (9)
Myocardial infarction 0.0% (0)
Aortic valve re-intervention (any) 3.1% (2)
Hemorrhagic event 71.9% (46)
Major bleeding 60.9% (39)
Minor bleeding 11.0% (7)
Bleeding event that requires transfusion 40.7% (26)
New permanent pacemaker insertion 1.6% (1)
Renal failure (dialysis required) 8.1% (5)
Dialysis lasting  30 days 1.6% (1)
1-year events
Death
From any cause 39.4% (25)
From cardiovascular cause 27.4% (17)
Repeat hospitalization 21.3% (10)
Stroke or TIA 10.4% (6)
TIA 1.6% (1)
Stroke 8.8% (5)
Minor 5.1% (3)
Major 1.6% (1)
Death from any cause or major stroke 39.3% (25)
Myocardial infarction 0.0% (0)
Aortic valve re-intervention (any) 7.6% (4)
Values are % (n).
CI  confidence interval; other abbreviations as in Table 1.predictors of 1-year mortality (Table 7).Discussion
The current report, drawn from a cohort of 419 patients
with severe symptomatic aortic stenosis who underwent
TF-TAVR, is the largest study to specifically evaluate the
incidence, predictors of, and impact of major VC on
long-term prognosis. The main results of the present study
are as follows: 1) major VC after TF-TAVR using the first
generation of large devices were frequent; 2) the occurrence
of major VC after TAVR was associated with bleeding
events, transfusions, and increased mortality; 3) the inci-
dence and impact of major VC seems to decrease in a
lower-risk population. The current study demonstrated the
prognostic impact of major VC after TAVR on short- and
long-term mortality. Indeed, major VC were associated
with a more than 4-fold increase in 30-day mortality.
Several other investigators have reported similar results.
Rodes-Cabau et al. (15) identified access site complications
as a potential factor associated with 30-day and cumulative
C Versus No Major VC Up to 30 Dayse of Major VC Versus No Major VC Up to 30 Days
Major Vascular
lications (n  355)
Combined
(n  419)
Hazard Ratio
[95% CI] p Value
3.1% (11) 4.8% (20) 4.87 [2.02–11.75] 0.0001
2.8% (10) 4.3% (18) 4.75 [1.87–12.04] 0.0003
5.7% (20) 5.8% (24) 1.13 [0.39–3.31] 0.82
0.6% (2) 0.7% (3) 2.92 [0.26–32.23] 0.36
5.1% (18) 5.0% (21) 0.94 [0.28–3.18] 0.92
2.8% (10) 2.9% (12) 1.13 [0.25–5.14] 0.88
1.1% (4) 1.2% (5) 1.42 [0.16–12.73] 0.75
5.4% (19) 6.7% (28) 2.72 [1.23–6.02] 0.01
0.0% (0) 0.0% (0) — —
2.3% (8) 2.4% (10) 1.40 [0.30–6.58] 0.67
13.6% (48) 22.5% (94) 7.60 [5.01–11.52] 0.0001
6.8% (24) 15.1% (63) 12.73 [7.57–21.42] 0.0001
7.1% (25) 7.7% (32) 1.60 [0.69–3.69] 0.26
5.4% (19) 10.8% (45) 9.23 [5.09–16.76] 0.0001
4.2% (15) 3.9% (16) 0.38 [0.05–2.86] 0.33
1.7% (6) 2.7% (11) 4.96 [1.51–16.27] 0.003
0.6% (2) 0.7% (3) 2.91 [0.26–32.08] 0.36
22.8% (81) 25.4% (106) 2.04 [1.30–3.19] 0.001
8.7% (29) 11.5% (46) 3.75 [2.06–6.83] 0.0001
18.5% (61) 18.7% (71) 1.02 [0.52–1.98] 0.96
8.5% (29) 8.8% (35) 1.23 [0.51–2.97] 0.64
1.6% (5) 1.6% (6) 1.27 [0.15–10.91] 0.83
7.0% (24) 7.2% (29) 1.22 [0.47–3.20] 0.68
4.1% (14) 4.2% (17) 1.26 [0.36–4.38] 0.72
1.8% (6) 1.8% (7) 1.00 [0.12–8.32] 1.00
24.5% (87) 26.8% (112) 1.86 [1.19–2.90] 0.006
0.4% (1) 0.3% (1) — 0.71
2.6% (9) 3.2% (13) 2.58 [0.79–8.39] 0.10jor Vrrenc
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Complate mortality (median follow-up of 8 months). Similarly,
1049JACC Vol. 60, No. 12, 2012 Généreux et al.
September 18, 2012:1043–52 Vascular Complications After TAVRThomas et al. (16), in the SOURCE (SAPIEN Aortic
Bioprosthesis European Outcome) registry, demonstrate a
Figure 3 Kaplan-Meier Curves Showing Cumulative Death Rate
Through 1 Year for Major VC
Comparison of the cumulative death rate through 1 year in patients with major
VC compared with patients with no major vascular complications (VC). Total
population (A), cohort 1B only (B), cohort 1A only (C). The impact of major VC
on mortality decreased from cohort 1B (B) to cohort 1A (C). CI  confidence
interval; HR  hazard ratio.numerically higher, but nonstatistically significant, rate ofdeath at 30 days in patients with major VC compared with
no major VC (12.2% vs. 5.6%, p  0.108). Ducrocq et al.
(4) also showed comparable results, with a 30-day mortality
of 11.1% in the VC group compared with 4.5% in the
non–VC group (p 0.42). Despite important differences in
outcome definitions and in the adjudication of events
between these studies and the PARTNER trial, these
findings highlight the prognostic importance of major VC
after TAVR.
Not surprisingly, major VC were associated with a high
rate of major bleeding (60.9%) and transfusions (40.7%) at
30 days in our cohort. These results parallel the early case
series published by Ducrocq et al. (4), in which 78% of
patients with VC needed a transfusion. Interestingly, more
episodes of acute renal failure requiring dialysis occurred in
the major VC group. This finding reflected the severity of
some of the major VC that occurred in our cohort, leading
to severe hemodynamic collapse and/or embolic events,
more transfusions, more contrast used, and eventually,
kidney function compromise. Also, more invasive strategies
(conversion to open heart surgery, hemodynamic support
devices) were used to manage major VC, reflecting the
severity of the initial vascular insult and may, per se, be
involved in the genesis of significant kidney injury. Con-
versely, the occurrence of minor VC had no impact on
short- and long-term mortality, and was associated with less
severe bleeding, fewer transfusions, and a lower rate of acute
kidney injury requiring renal therapy support.
Important predictors of major VC after TAVR have been
identified by multiple groups. Early experience of the site
and operators, severe femoral artery calcification, minimal
artery diameter, and a sheath-to femoral-artery ratio 1.05
have been associated with the occurrence of VC (7,8). In the
current analysis, female sex was the only identifiable inde-
pendent predictor of major VC after TAVR. The smaller
vessel diameters encountered in women paired with the
relatively large first-generation introducer-sheath catheter
system used in the PARTNER trial (22-F or 24-F) may
partially explain this finding. This presumption has been
confirmed recently by Hayashida et al. (17), in which
women had smaller minimal femoral sizes, higher sheath-
to-artery ratios, and were more likely to experience iliac
complications after TAVR compared with men. However,
even after adjusting for sheath-to-femoral-artery ratio, fe-
male sex remained a strong independent predictor of major
VC after TAVR, implying that impact of sex goes beyond
these simplistic explanations. An intrinsic increased vulner-
ability to periprocedural complication during and early after
an invasive procedure may be present in women. Exact
mechanisms for this finding remain elusive and warrant
further investigation. Interestingly, our result suggests that
although female sex is a strong predictor of periprocedural
(vascular) complications (Table 6), at 1 year, female sex is
associated with a reduction in all-cause mortality (Table 7).
This finding has also been reported by another group (17).
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is complex, and a more detailed analysis is needed.
Full percutaneous TAVR with the use of closure devices
was performed in only 24.9% of patients in the combined
population of cohorts B and A. This low rate, in contrast
with contemporary practice, may be explained by the fact
that many centers among the PARTNER trial sites were at
the beginning of their learning curve. Also, current closure
devices (Prostar XL and PerClose ProGlide, both Abbott
Vascular, Santa Clara, California) are only approved for
closure of 10-F sheath holes in the United States. Access
and closure via surgical cutdown may have been viewed as
more predictable, offering more direct control during ad-
verse events, especially in less experienced hands. Although
no studies have specifically compared both approaches,
recent data suggest that a full percutaneous procedure,
helped by adjunctive techniques, can be performed with a
low rate of VC and bleeding events, especially with the use
30-Day and 1-Year Event Rates According to the Occurrence of MiTable 5 30-Day and 1-Year Event Rates According to the Occu
Minor Vascular
Complications (n  50)
30-day events
Death
From any cause 4.0% (2)
From cardiovascular cause 4.0% (2)
Stroke or TIA 10.0% (5)
TIA 2.0% (1)
Stroke 8.0% (4)
Minor 6.0% (3)
Major 2.0% (1)
Death from any cause or major stroke 8.0% (4)
Myocardial infarction 0.0% (0)
Aortic valve re-intervention (any) 0.0% (0)
Hemorrhagic Event 40.1% (20)
Major bleeding 12.0% (6)
Minor bleeding 28.0% (14)
Bleeding event that requires
transfusion
8.0% (4)
New permanent pacemaker insertion 6.0% (3)
Renal failure (dialysis required) 4.0% (2)
Dialysis lasting 30 days 2.0% (1)
1-year events
Death
From any cause 26.0% (13)
From cardiovascular cause 6.3% (3)
Repeat hospitalization 31.8% (15)
Stroke or TIA 12.4% (6)
TIA 4.4% (2)
Stroke 8.0% (4)
Minor 6.0% (3)
Major 2.0% (1)
Death from any cause or major stroke 0.0% (0)
Myocardial infarction 0.0% (0)
Aortic-valve re-intervention (any) 0.0% (0)
Values are % (n).
Abbreviations as in Tables 1 and 4.of a smaller diameter sheath (5–7). In addition, techniquessuch as the “cross-over balloon occlusion technique,” in
which an endovascular balloon, brought either via the
contralateral femoral access site or via the radial artery, is
inflated proximal to the site of arteriotomy prior to the large
sheath removal, has allowed safer execution of a fully
percutaneous TAVR procedure (5,6,18). Although percu-
taneous closure has been routinely adopted by many centers
and performed with a high rate of success after TAVR, a
learning curve and specific complications should be ac-
knowledged (6,19). The superiority of one approach (e.g.,
surgical cutdown) compared with the other (e.g., closure
device) still remains a matter of debate, and outcomes are
also expected to vary according to the expertise of operators.
Several authors have already demonstrated the impor-
tance of increased experience and improved device systems
(20–22). Toggweiler et al. (7) recently demonstrated the
combined effect of increased experience paired with smaller
sheath size use on the occurrence of VC. The rate of major
C Versus No VC Up to 30 Dayse of Minor VC Versus No VC Up to 30 Days
No Vascular
ications (n  305)
Combined
(n  355)
Hazard Ratio
[95% CI] p Value
3.0% (9) 3.1% (11) 1.35 [0.29–6.27] 0.70
2.6% (8) 2.8% (10) 1.52 [0.32–7.17] 0.59
4.9% (15) 5.7% (20) 2.07 [0.75–5.71] 0.15
0.3% (1) 0.6% (2) 6.10 [0.38–97.54] 0.14
4.6% (14) 5.1% (18) 1.77 [0.58–5.38] 0.30
2.3% (7) 2.8% (10) 2.66 [0.69–10.29] 0.14
1.0% (3) 1.1% (4) 2.02 [0.21–19.39] 0.53
4.9% (15) 5.4% (19) 1.67 [0.56,5.04] 0.35
0.0% (0) 0.0% (0) — —
2.6% (8) 2.3% (8) — 0.25
9.2% (28) 13.6% (48) 5.15 [2.90–9.17] 0.0001
6.0% (18) 6.8% (24) 2.12 [0.84–5.35] 0.10
3.6% (11) 7.1% (25) 8.36 [3.79–18.43] 0.0001
5.0% (15) 5.4% (19) 1.67 [0.55–5.02] 0.36
4.0% (12) 4.2% (15) 1.57 [0.44–5.56] 0.48
1.3% (4) 1.7% (6) 3.04 [0.56–16.58] 0.18
0.3% (1) 0.6% (2) 6.07 [0.38–97.05] 0.15
22.3% (68) 22.8% (81) 1.20 [0.67–2.18] 0.54
9.0% (26) 8.7% (29) 0.72 [0.22–2.39] 0.59
16.3% (46) 18.5% (61) 2.29 [1.28–4.10] 0.004
7.9% (23) 8.5% (29) 1.65 [0.67–4.06] 0.27
1.1% (3) 1.6% (5) 4.32 [0.72–25.86] 0.08
6.8% (20) 7.0% (24) 1.25 [0.43–3.65] 0.68
3.8% (11) 4.1% (14) 1.71 [0.48–6.12] 0.40
1.8% (5) 1.8% (6) 1.23 [0.14–10.50] 0.85
0.4% (1) 0.4% (1) — 0.69
0.4% (1) 0.3% (1) — 0.71
3.0% (9) 2.6% (9) — 0.22nor Vrrenc
ComplVC went from 8.0% in 2009, using mainly a first-generation
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18- to 19-F sheath system. From the PARTNER trial
experience, VC not only decreased in cohort A patients
(high-risk but operable) as compared with cohort B patients
(nonoperable), but also had less impact on short- and
long-term mortality (Fig. 3C). Many factors could explain
these findings: 1) temporally speaking, cohort B was one of
the first TAVR studies to be performed in the United
States, and all enrolling sites/operators were in the early
stages of experience, learning about appropriate patient
selection, vascular screening, and crucial technical details of
the procedure; 2) patients from cohort B, being sicker, were
more fragile and less inclined to tolerate any major compli-
cations; and 3) the transapical approach became available in
cohort A, in cases where the iliofemoral vessels were not
suitable for the TF approach, making less likely the scenario
of “borderline” vessel diameter or vascular anatomy being
attempted by the TF approach. These findings underline
the magnitude of impact and the synergy between enhanced
operator skills, TAVR team experience, and device im-
provement. These 3 factors are vital if the full clinical
Figure 4 Kaplan-Meier Curves Showing Cumulative Death Rate
Through 1 Year for Minor VC
Comparison of the cumulative death rate through 1 year between patients with
minor VC compared with patients with no VC at all. The occurrence of minor VC
did not impact mortality. Abbreviations as in Figure 3.
Independent Clinical Predictorsof Major VCs Within 30 DaysTable 6 Indepe dent Clinical Predictorsof Major VCs Within 30 Days
Predictors Estimate Hazard Ratio [95% CI] p Value
Female 0.8388 2.31 [1.08–4.98] 0.03
SFAR 1.05 0.5026 1.65 [0.81–3.36] 0.16
Diabetes, insulin 1.0720 2.92 [0.67–12.75] 0.15
Peripheral disease 0.3010 1.35 [0.71–2.58] 0.36
BSA, m2 0.4892 0.61 [0.15–2.53] 0.49
Renal disease at baseline 0.0424 0.96 [0.40–2.27] 0.92
Variables included in the model were BSA, sex, SFAR, insulin-dependent diabetes, peripheral
disease, and renal disease at baseline.
Abbreviations as in Tables 1, 2, and 4.potential of the TAVR procedure is to be realized, especially
when involving a lower-risk population.
Study limitations. As an observational post hoc analysis, it
can only identify correlations, not prove causality. Despite
adjustment for potential confounders, unmeasured variables
may not have been fully controlled. All these findings, there-
fore, should be considered hypothesis generating. Only suitable
iliofemoral vessel access was included in the PARTNER trial
nd considered for TF-TAVR. Although rigorous vascular
creening, including angiograms, computed tomography
cans, and/or peripheral intravascular ultrasound, was per-
ormed before randomization, no core laboratory analysis or
rospective data collection of these imaging studies was
ncluded in case report forms, and all analyses were per-
ormed retrospectively with available imaging data. Finally,
s mentioned, the PARTNER trial was performed using
he first-generation devices with operators and sites at the
eginning of their learning curve.
onclusions
ajor VC were frequent after TF-TAVR in the PARTNER
rial using first-generation devices and were associated with a
igh 1-year mortality. However, the incidence and the impact
f major VC decreased with lower-risk populations.
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